The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | KarMMA-2 cohort 2b update: ide-cel for transplant-ineligible patients with high-risk myeloma
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, presents the results of one arm of the Phase II KarMMA-2 (NCT03601078) trial investigating idecabtagene vicleucel (ide-cel), a BCMA-targeted CAR T-cell therapy, in patients with clinical transplant-ineligible high-risk multiple myeloma (MM). The overall response rate (ORR) was greater than 90%, and the complete response (CR) rate was greater than 60%, with most of these patients achieving measurable residual disease (MRD) negativity. At 21 months, the median progression-free survival (PFS) has not yet been reached, with an expected PFS of 63% at 2 years. The safety profile of ide-cel was favorable. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
